GARDEN CITY, N.Y.--(BUSINESS WIRE)--ImaCor Inc., the developer of the world’s only hemodynamic transesophageal echocardiography (hTEE™) management device, announced today that transplant and mechanical circulatory support (MCS) physicians from around the world gathered in Montreal at an hTEE symposium to hear from heart failure experts about the value of hTEE management. The symposium took place Wednesday, April 24th during the 33rd Annual Meeting and Scientific Sessions of the International Society for Heart & Lung Transplantation (ISHLT).
“The key to hTEE’s impact on the care of MCS patients is the ability to assess the RV”
hTEE is the only technology in critical care that provides continuously available, direct visualization of heart filling and function at the bedside. Presenters from Stanford Hospital (CA), Newark Beth Israel Medical Center (NJ), and Thomas Jefferson University Hospital (PA) shared how hTEE provides a more complete way to manage their MCS patients. Clinical studies and case reports presented by the clinicians illustrated that using hTEE helps protect the right ventricle (RV) in post-operative MCS management, avoids unnecessary re-operations, and facilitates the better management of complications, thereby lowering ICU costs.
“Direct visualization of ventricular function reduces the complexity associated with the post-operative care of heart failure patients,” said Peter Lee MD, Cardiothoracic Surgeon at Stanford Hospital. “hTEE has become an essential tool in our ICU to meet the critical, patient management needs created by use of these evolving, life-saving MCS technologies.”
“The key to hTEE’s impact on the care of MCS patients is the ability to assess the RV,” commented Scott Roth MD, the Co-Founder/CMO of ImaCor. “RV dysfunction is prevalent in MCS patients, compounding their already high-risk profile. hTEE continuously provides a window to the RV, enabling clinicians to manage dysfunction from its inception. There is simply no other way to do this easily at the ICU bedside.”
“Hospitals using hTEE on complex patients, i.e., MCS, are seeing the benefit via improved outcomes and reduction in complication costs,” stated Peter Pellerito, President/CEO of ImaCor. “At yesterday's symposium, physicians once again underscored the synergistic use of technology – matching costly, complex patients and technologies with the cost-effective, simplified hTEE approach.”
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare resources. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™, Zura EVO™, Adaptaflex™, and ClariTEE® are trademarks of ImaCor, Inc. For more information, please visit our website at www.imacorinc.com.